On June 22, the NMPA official website showed that AstraZeneca’s Osimertinib has been approved for a new indication in China (Acceptance No.: JXHS2500107/8), in combination with Savolitinib for the treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have EGFR gene mutation positivity, have progressed after prior EGFR tyrosine kinase inhibitor (TKI) therapy, and have MET amplification.
Osimertinib is an irreversible third-generation EGFR-TKI independently developed by AstraZeneca. As the world’s first third-generation EGFR-TKI, since its first approval in the United States in 2015, its global sales reached $7.254 billion by 2025, making it AstraZeneca’s second-highest revenue-generating product.
Buy TAGRISSO®Osimertinib from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
